Fibromyalgia Trial, Recruiting NCT06866444 Sponsor: University of Utah Condition: Fibromyalgia
Back to Fibromyalgia

Fibromyalgia Trial, Recruiting

NCT06866444
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You must have been diagnosed with Fibromyalgia
  • You must have been taking Duloxetine (60 mg per day) for at least 8 weeks

Who may not be able to join:

  • You may not be able to join if you are pregnant
  • You may not be able to join if you have been told by a doctor that you have kidney or liver problems, or if you have ever been on dialysis (a treatment that filters your blood when your kidneys cannot)
  • You may not be able to join if you need an interpreter to communicate during the trial
  • You may not be able to join if you have another ongoing illness (other than Fibromyalgia) that causes long-term pain and tiredness, such as cancer currently being treated with chemotherapy, Parkinson's disease, or Multiple Sclerosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jake Steenblick, DNP, University of Utah

Phone: 801-585-1216

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Duloxetine concentrations across metabolizer phenotypes, 3 groups; Measure inhibitors and inducers of CYP1A2 and CYP2D6 in blood sample

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov